A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age
1/2상
완료
NCT05975099
| 대상 질환 | Lyme Disease |
|---|
| 임상 단계 | 1/2상 |
|---|
| 스폰서 | ModernaTX, Inc. |
|---|
| 상태 | 완료 |
|---|
| 참여자 수 | 807 명 |
|---|
| 중재(약물) | mRNA-1975, mRNA-1982 |
|---|
| 시작일 | 2023년 7월 26일 |
|---|
| 완료일 | 2025년 5월 30일 |
|---|
| 결과 공개일 | 2026년 7월 30일 |
|---|
요약
The purpose of this study is to evaluate the safety and immunogenicity in parallel of heptavalent mRNA-1975 and monovalent mRNA-1982 against Lyme disease in healthy adult participants.
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) Within 7 Days After Day 1 Injection
Up to 7 days after Day 1 injection · Participants
| mRNA-1975 Dose Level 1 | 70 Participants |
|---|
| mRNA-1975 Dose Level 2 | 80 Participants |
|---|
| mRNA-1975 Dose Level 3 | 82 Participants |
|---|
| mRNA-1975 Dose Level 4 | 91 Participants |
|---|
| mRNA-1982 Dose Level 1 | 64 Participants |
|---|
| mRNA-1982 Dose Level 2 | 77 Participants |
|---|
Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 57 Injection
Up to 7 days after Day 57 injection · Participants
| mRNA-1975 Dose Level 1 | 79 Participants |
|---|
| mRNA-1975 Dose Level 2 | 80 Participants |
|---|
| mRNA-1975 Dose Level 3 | 90 Participants |
|---|
| mRNA-1975 Dose Level 4 | 96 Participants |
|---|
| mRNA-1982 Dose Level 1 | 70 Participants |
|---|
| mRNA-1982 Dose Level 2 | 82 Participants |
|---|
Number of Participants With Solicited Local and Systemic ARs Within 7 Days After Day 169 Injection
Up to 7 days after Day 169 injection · Participants
| mRNA-1975 Dose Level 1 | 81 Participants |
|---|
| mRNA-1975 Dose Level 2 | 87 Participants |
|---|
| mRNA-1975 Dose Level 3 | 81 Participants |
|---|
| mRNA-1975 Dose Level 4 | 92 Participants |
|---|
| mRNA-1982 Dose Level 1 | 76 Participants |
|---|
| mRNA-1982 Dose Level 2 | 82 Participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.